PHBBF (Pharmaron Beijing Co) Issuance of Debt: $430 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHBBF Pharmaron Beijing Co Ltd PHBBF
85 GF Score
Price $1.93
GF Value $1.32
! 9 Warning Signs
View Full Analysis

What is Pharmaron Beijing Co Issuance of Debt?

Pharmaron Beijing Co PHBBF 85 Issuance of Debt is $430 Mil as of Mar. 2026. GuruFocus rates PHBBF with a GF Score™ of 85/100 and a GF Value™ of $1.32. The stock has 9 warning signs investors should review.

Pharmaron Beijing Co's Issuance of Debt for the three months ended in Mar. 2026 was $46 Mil.

Pharmaron Beijing Co's Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $430 Mil.

Pharmaron Beijing Co Issuance of Debt Related Terms

Pharmaron Beijing Co Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Pharmaron Beijing Co's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaron Beijing Co Issuance of Debt Chart

Pharmaron Beijing Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 725.58 84.60 584.14 181.57 406.96

Pharmaron Beijing Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.44 42.09 122.83 218.78 46.27
PHBBF
85GF Score
Pharmaron Beijing Co Ltd PHBBF
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmaron Beijing Co Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $430 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of $430 Mil mean?
Pharmaron Beijing Co (PHBBF) has a Issuance of Debt of $430 Mil as of Mar. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Pharmaron Beijing Co and its competitors.
Is Pharmaron Beijing Co's Issuance of Debt too high?
Pharmaron Beijing Co's current Issuance of Debt is $430 Mil. Overall, Pharmaron Beijing Co has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Issuance of Debt compare to VRTX and REGN?
Pharmaron Beijing Co's Issuance of Debt of $430 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Pharmaron Beijing Co and its competitors. Pharmaron Beijing Co's current Issuance of Debt is $430 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Pharmaron Beijing Co (PHBBF) has a current Issuance of Debt of $430 Mil. The stock's GF Value™ is $1.32, compared to a current price of $1.93 — trading 46.2% above its estimated fair value. The current Issuance of Debt is $430 Mil. Pharmaron Beijing Co's overall GF Score™ is 85/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Pharmaron Beijing Co (PHBBF), the current Issuance of Debt is $430 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmaron Beijing Co (PHBBF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued. The current stock price of $1.93 is trading 46.2% above its estimated GF Value™ of $1.32.

Key valuation signals for PHBBF:

  • Issuance of Debt: $430 Mil
  • GF Value™: $1.32 vs. price of $1.93 (46.2% above fair value)
  • GF Score™: 85/100 with 9 warning signs

No single metric tells the full story. See the PHBBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmaron Beijing Co Business Description

Address 6 Tai-He Road, 8th Floor, Block 1, Beijing Economic Technological Development Area, Beijing, CHN, 100176
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
85GF Score

Get the complete analysis for PHBBF

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.93
Price
$1.32
GF Value